These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24550171)
1. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Sieper J; Braun J; Kay J; Badalamenti S; Radin AR; Jiao L; Fiore S; Momtahen T; Yancopoulos GD; Stahl N; Inman RD Ann Rheum Dis; 2015 Jun; 74(6):1051-7. PubMed ID: 24550171 [TBL] [Abstract][Full Text] [Related]
2. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067 [TBL] [Abstract][Full Text] [Related]
4. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H; Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964 [TBL] [Abstract][Full Text] [Related]
5. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184 [TBL] [Abstract][Full Text] [Related]
6. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Sieper J; Porter-Brown B; Thompson L; Harari O; Dougados M Ann Rheum Dis; 2014 Jan; 73(1):95-100. PubMed ID: 23765873 [TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250 [TBL] [Abstract][Full Text] [Related]
8. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J; Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC; Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Wei JC; Kim TH; Kishimoto M; Ogusu N; Jeong H; Kobayashi S; Ann Rheum Dis; 2021 Aug; 80(8):1014-1021. PubMed ID: 33827787 [TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study. Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983 [TBL] [Abstract][Full Text] [Related]
15. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC; Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E; Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755 [TBL] [Abstract][Full Text] [Related]
17. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246 [TBL] [Abstract][Full Text] [Related]
18. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410 [TBL] [Abstract][Full Text] [Related]
19. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208 [TBL] [Abstract][Full Text] [Related]
20. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]